Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, van Vlierberghe RLP, Blok EJ, Giardiello D, Sanders J, Van de Vijver K, Horlings HM, Kuppen PJK, Linn SC, Schmidt MK, Kok M. Sobral-Leite M, et al. Among authors: horlings hm. Breast Cancer Res. 2019 Aug 7;21(1):90. doi: 10.1186/s13058-019-1176-2. Breast Cancer Res. 2019. PMID: 31391067 Free PMC article.
PatchSorter: a high throughput deep learning digital pathology tool for object labeling.
Walker C, Talawalla T, Toth R, Ambekar A, Rea K, Chamian O, Fan F, Berezowska S, Rottenberg S, Madabhushi A, Maillard M, Barisoni L, Horlings HM, Janowczyk A. Walker C, et al. Among authors: horlings hm. NPJ Digit Med. 2024 Jun 20;7(1):164. doi: 10.1038/s41746-024-01150-4. NPJ Digit Med. 2024. PMID: 38902336 Free PMC article.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. Berns K, et al. Among authors: horlings hm. Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030. Cancer Cell. 2007. PMID: 17936563 Free article. Clinical Trial.
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.
Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. Reyal F, et al. Among authors: horlings hm. Breast Cancer Res. 2008;10(6):R93. doi: 10.1186/bcr2192. Epub 2008 Nov 13. Breast Cancer Res. 2008. PMID: 19014521 Free PMC article.
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen M. Pietersen AM, et al. Among authors: horlings hm. Breast Cancer Res. 2008;10(6):R109. doi: 10.1186/bcr2214. Epub 2008 Dec 19. Breast Cancer Res. 2008. PMID: 19099573 Free PMC article.
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT, Wesseling J. Hartog H, et al. Among authors: horlings hm. Breast Cancer Res Treat. 2011 Oct;129(3):725-36. doi: 10.1007/s10549-010-1256-6. Epub 2010 Nov 24. Breast Cancer Res Treat. 2011. PMID: 21107683
138 results